CA-INSEEGO-CORP
26.7.2022 13:03:16 CEST | Business Wire | Press release
Inseego Corp. (Nasdaq: INSG) announced today that the Inseego Wavemaker™ FX2000 5G indoor router is now being sold to customers on the Three Sweden network. Three Sweden is part of Three Group Europe, which includes networks in Austria, Denmark, Italy, Ireland, Sweden and the United Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220726005524/en/
The award-winning FX2000 fixed wireless access (FWA) router can deliver gigabit speeds for fast and reliable internet access, along with Wi-Fi 6 for up to 30 devices, making it ideal for remote work, streaming and gaming. With its small, elegant design and simple setup, it fits into any environment, from home offices to summer cottages.
“We’re proud to provide this fixed wireless access solution to Three Sweden and their customers,” said Simon Rayne, senior vice president and managing director, UK, EMEA, and Asia-Pacific for Inseego. “This is the first commercial launch of our FX2000 with a European carrier, and we look forward to many more. Our 5G solutions are changing the way millions of people stay connected at home, in the office, and on the move.”
“This router is an excellent choice for our customers who want the speed and simplicity of 5G home internet,” said Rune Pedersen, CCO Consumer Market at Three Sweden. “Combined with our unlimited 3Bredband Max, it’s an easy, affordable way to plug into the power of new 5G experiences.”
Speed, simplicity and flexibility: With its small footprint and low profile, the FX2000 fits into any setting. It can be placed on a tabletop or desktop and moved easily when relocating to a new home or office.
Easy setup and management: The FX2000 can be set up by anyone (no service technician needed) in just a few minutes. The Inseego Mobile smartphone app makes it easy to choose the best placement and manage the FX2000 with user-friendly control settings.
Best-in-class performance: With Inseego’s industry-leading antenna and RF technology, the FX2000 can deliver peak 5G speeds over 1 Gbps (depending on network coverage), along with fallback to Cat 22 LTE. Sustained high throughput and low latency 5G connections are ideal for applications such as video conferencing, streaming media, AR/VR and cloud computing. The FX2000 supports dual-band Wi-Fi 6 for up to 30 connected devices, as well as an ethernet LAN port and USB port, to connect up to 32 devices simultaneously. The ethernet LAN port can also be connected to other routing devices.
Enterprise-grade security: Designed and developed in the U.S. with multiple layers of advanced security, the FX2000 safeguards data with advanced encryption, hacker prevention, password protection, OpenVPN, guest Wi-Fi network and more. Robust authentication protects against cyber threats and allows customers to connect with confidence.
To learn more about Inseego 5G products and solutions, please go to inseego.com .
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Inseego’s mobile broadband, fixed wireless access (FWA) solutions and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of innovative products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service provider, enterprise, and government entities worldwide. www.inseego.com #Putting5GtoWork
Inseego 5G FX2000 chipset: Qualcomm® Snapdragon® X55 5G Modem-RF System.
©2022. Inseego Corp. All rights reserved. The Inseego name and logo name and logo are registered trademarks and Wavemaker is a trademark of Inseego Corp. Other Company, product or service names mentioned herein are the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005524/en/
Link:
Social Media:
https://www.facebook.com/Inseego/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom